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Introduction. Metabolic conditions, including type 2 diabetes, have been related to hepatocellular carcinoma (HCC) risk. We have
further analyzed the role of diabetes and antidiabetic treatments onHCC.Methods. Data derived from a hospital-based case-control
study (Italy, 2005–2012) on 224 HCC patients and 389 controls. Odds ratios (ORs) were estimated usingmultiple logistic regression
models. Results. Sixty-nine (30.9%) cases versus 52 (13.5%) controls reported a diabetes diagnosis, corresponding to a multivariate
OR of 2.25 (95% confidence interval, CI = 1.42–3.56). A stronger excess risk emerged for a longer time since diabetes diagnosis (OR
= 2.96 for <10 years and 5.33 for ≥10 years). Oral therapies were inversely, though not significantly, related to HCC risk, OR being
0.44 for metformin and 0.88 for sulfonylureas; conversely, insulin was nonsignificantly directly associated (OR = 1.90). Compared
to nondiabetic subjects who were never smokers, those who were diabetics and ever smokers had anOR of 6.61 (95%CI 3.31–13.25).
Conclusion. Our study confirms an over 2-fold excess HCC risk in diabetics, with a stronger excess risk in diabetic subjects who are
also tobacco smokers. Metformin may decrease the risk of HCC, whereas insulin may increase the risk.
1. Introduction
Liver cancer is the seventh most common cancer and the
third cause of cancer deaths worldwide [1, 2]. In Italy, 2950
deaths from liver cancer were registered in 2008 in men (3%
of all cancer deaths) and 1500 (2% of all cancer deaths) in
women [3].
Hepatocellular carcinoma (HCC) is the most common
histological type of liver cancer, accounting for up to 85% of
cases [4]. The major recognized factors for HCC are chronic
hepatitis B virus (HBV) and hepatitis C virus (HCV) infec-
tions, heavy alcohol drinking, and tobacco smoking [4–8].
Several epidemiological studies have indicated that type
2 diabetes mellitus is also associated with an increased risk of
HCC [9–15]. Ameta-analysis of epidemiological studies pub-
lished up to February 2011 reported a significant relative risk
(RR) of 2.4 from 17 case-control studies, 2.2 from 25 cohort
studies, and a RR of 2.4 from 7 cohort studies on mortality
from HCC [13]. A significant trend with duration of diabetes
was observed in 6 studies, with a RR of 3.3 for 10 years since
diabetes diagnosis. Moreover, the presence of diabetes has
been associated with metastatic HCC and with worse prog-
nosis [16, 17].
Although data on the role of drugs for the treatment of
type 2 diabetes in HCC are limited, there are indications that
metformin, sulfonylureas [18], and thiazolidinediones [19]
are associated with a reduced risk of HCC, whereas insulin
may increase the risk [20].
We have further analyzed the role of diabetes and antidia-
betic treatments inHCCrisk using data fromahospital-based
case-control study conducted in Italy.
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2. Materials and Methods
2.1. Selection of Cases and Controls. Study subjects were
recruited among patients admitted to the Teaching Hospital
“Agostino Gemelli” of the Universita` Cattolica del Sacro
Cuore, Rome, Italy, from January 2005 until July 2012, and eli-
gibility was restricted to Caucasian individuals born in Italy.
In particular, cases were 224 patients with HCC recruited
among subjects referred to the Outpatient Liver Unit of the
hospital. The diagnosis of HCC was performed according to
the AASLD guidelines [21]. Controls were 389 patients from
the same hospital, enrolled during the same time period.
Around 50%of the controlswere outpatients, and the remain-
ing were patients undergoing surgical interventions (laparo-
scopic cholecystectomy, appendicitis, and inguinal hernia)
or admitted for a wide spectrum of other acute nonneoplastic
diseases. The study was conducted according to the Declara-
tion of Helsinki and was approved by the Ethical Committee
of Universita` Cattolica del Sacro Cuore. A written informed
consent was obtained from all study subjects.
2.2. Data Collection. HCC cases and controls were inter-
viewed by trained interviewers using a structured question-
naire to collect information on demographics, lifestyle habits
(including tobacco smoking and alcohol drinking), andmed-
ical history. In particular, the questionnaire included infor-
mation on history and duration of diabetes and use of antidi-
abetic drugs (metformin, sulfonylureas, and insulin). Ques-
tions focused on the time period ending one year prior to
diagnosis for cases and on the year prior to the interview date
for controls.
2.3. Data Analysis. Odds ratios (ORs) for HCC and their
corresponding 95% confidence intervals (CI) were estimated
using multiple logistic regression models [22] including
terms for age, sex, tobacco smoking, and alcohol drinking.
To test for multiplicative interaction between diabetes and
tobacco smoking, we compared the difference in−2 log likeli-
hood of themodelswith andwithout an interaction termwith
the 𝜒2 distribution with one degree of freedom.Moreover, we
tested for additive interaction using the relative excess risk
due to interaction (RERI) and the synergy index (𝑆) [23] and
tested their significance using the delta method [24].
3. Results
Table 1 shows the distribution of HCC cases and correspond-
ing controls according to selected factors. Cases were some-
what older than controls, more frequently of male sex and
ever smokers. History of hepatitis was reported by 71% of
cases and 3% of controls.
The distribution of HCC cases and controls and corre-
sponding ORs according to history of diabetes and use of
antidiabetic drugs are given in Table 2. Sixty-nine (30.9%)
cases versus 52 (13.5%) controls reported a diagnosis of dia-
betes, corresponding to a multivariate OR of 2.25 (95% CI =
1.42–3.56). A stronger excess risk was observed for a longer
time since diagnosis of diabetes (OR = 2.96 for <10 years
Table 1: Distribution of 224 cases of hepatocellular carcinoma
(HCC) and 389 controls according to selected factors (Italy, 2005–
2012).
HCC cases Controls
𝑁 (%) 𝑁 %
Age (years)
<60 44 (19.6) 154 (39.6)
60–69 81 (36.2) 104 (26.7)
≥70 99 (44.3) 131 (33.7)
Sex
Male 162 (72.3) 240 (61.7)
Female 62 (27.7) 149 (38.3)
Tobacco smokinga
Never smoker 86 (39.1) 208 (54.2)
Ever smoker 134 (60.9) 176 (45.8)
Hepatitisa,b
No 65 (29.0) 269 (97.1)
Yes 159 (71.0) 11 (2.9)
aThe sum does not add up to the total because of some missing values.
bHepatitis includes hepatitis B and/or C.
and 5.33 for ≥10 years). Subjects using oral antidiabetic drugs
had a nonsignificantly reduced HCC risk as compared to
nonusers: the OR was 0.51 for use of any oral antidiabetic
drug, 0.44 for metformin, and 0.88 for sulfonylureas. Con-
versely, subjects using insulin had a nonsignificantly higher
risk of HCC as compared to nonusers (OR = 1.90).
The combined effect of diabetes and tobacco smoking
on HCC risk is shown in Table 3. Compared to nondiabetic
subjects who were never smokers, those who were diabetics
and ever smokers had an OR of 6.61 (95% CI = 3.31–13.25).
The interaction was significant on an additive scale (RERI =
4.27, 𝑃 = 0.052 and 𝑆 = 4.15, 𝑃 = 0.013), and also borderline
significant on a multiplicative one (𝜒2 = 3.26; 𝑃 = 0.071).
4. Discussion
In this study, subjects with diabetes have an over 2-fold excess
risk ofHCC, in linewith the evidence from several other case-
control and cohort studies [11–13]. Further, HCC risk was
higher in subjects with a longer history of diabetes. Again this
is in agreement with the evidence from a few other investiga-
tions [13, 20, 25].
The mechanistic role of diabetes in HCC cancerogenesis
is not straightforward. Diabetes may be a consequence of
chronic liver diseases (such as cirrhosis, nonalcoholic fatty
liver disease, and steatosis) [26, 27]. However, the persistence
of an excess risk many years since diagnosis suggests that
diabetes may be a real cause of HCC. Hyperinsulinemia
and insulin resistance, which characterize diabetes, and the
consequent upregulation of the insulin-like growth factor-
1/insulin receptor substrate-1 system, may also explain the
association between diabetes and HCC [28, 29]. Changes in
the hepatic activity and mitosis related to metabolic alter-
ations or to impaired liver function in diabetics are other
possible explanations of the association observed [30].
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Table 2: Distributiona of 224 hepatocellular carcinoma (HCC) cases and 389 controls, and corresponding odds ratios (OR) and 95%
confidence intervals (CI), according to history of diabetes (Italy, 2005–2012).
HCC cases Controls ORb (95% CI)
𝑁 (%) 𝑁 (%)
Diabetes
No 154 (69.1) 332 (86.5) 1c
Yes 69 (30.9) 52 (13.5) 2.25 (1.42–3.56)
Years of diabetes
<10 9 (5.1) 7 (2.0) 2.96 (0.92–9.45)
≥10 12 (6.9) 3 (0.9) 5.33 (1.34–21.10)
Oral antidiabetic drugs
Nonusers 46 (20.6) 26 (6.8) 1c
Users 23 (10.3) 26 (6.8) 0.51 (0.21–1.28)
Metformin
Nonusers 57 (25.6) 36 (9.4) 1c
Users 12 (5.4) 16 (4.2) 0.44 (0.15–1.27)
Sulfonylureas
Nonusers 58 (26.0) 43 (11.2) 1c
Users 11 (4.9) 9 (2.3) 0.88 (0.24–3.19)
Insulin
Nonusers 36 (16.1) 34 (8.9) 1c
Users 33 (14.8) 18 (4.7) 1.90 (0.74–4.88)
aThe sum does not add up to the total because of some missing values.
bEstimates adjusted for age, sex, tobacco smoking, and alcohol drinking.
cReference category.
Table 3: Distributiona of 224 hepatocellular carcinoma (HCC) cases
and 389 controls and corresponding odds ratiosb (OR) and 95%
confidence intervals (CI), according to the combination of smoking
and diabetes (Italy, 2005–2012).
Tobacco smoking
History of diabetes
Cases : controls, OR (95% CI)
No Yes
Never 62 : 178 24 : 29
1c 1.54 (0.79–2.99)
Ever 90 : 154 44 : 21
1.82 (1.14–2.90) 6.61 (3.31–13.25)
aThe sum does not add up to the total because of some missing values.
bEstimates adjusted for age, sex, and alcohol drinking.
cReference category.
Our study suggests that use of oral antidiabetic drugs, in
particular metformin, reduces the risk of HCC, while insulin
is associatedwith an increased risk. A fewother investigations
found an inverse association with metformin [31–34] and a
direct onewith insulin [35–37] and also sulfonylureas [31, 32].
This is in line with the observation that metformin reduces
insulin resistance, suppresses tumour formation, and inhibits
cell growth, while insulin may promote carcinogenesis [38,
39]. However, potential confounders, such as the severity of
diabetes and the variable baseline characteristics of patients
using different drugs may influence the association between
antidiabetic drugs and the subsequent risk of developing
HCC.
Cases and controls in our study came from comparable
catchment areas, were interviewed by uniformly trained
interviewers, and were unaware of a possible link between
diabetes and liver cancer, thereby reducing the likelihood of
potential selection and recall bias. Our study has however
some limitations. First, our questionnaire recorded frequency
of alcohol consumption one year before cancer diagnosis (for
cases) or interview date (for controls), and we have no infor-
mation on duration of use or lifetime alcohol intake. Thus,
alcohol information was not interpretable in our database
due to frequent cessation of alcohol consumption in subjects
with hepatitis and other chronic liver diseases. Consequently,
we used information on alcohol only as a covariate for
multivariate analysis, though we recognize that this may have
led to some underadjustment. In the absence of allowance for
alcohol, theOR for diabetes was 2.46 (95%CI 1.60–3.79), thus
suggesting that even more accurate allowance for alcohol
is unlikely to largely or totally explain the association with
diabetes. Anyway, alcohol consumptionwasmoderately asso-
ciatedwith liver cancer [40]. Second, information onhepatitis
was valid in cases, since it was based on third generation
immunoassay; this does not apply to all controls, though
the almost 3% prevalence of hepatitis is in broad agreement
with data from the Italian general population [5]. When we
added a term for hepatitis to the model, the OR for diabetes
became 4.75 (95%CI, 2.54–8.86).This indicates that the asso-
ciation between diabetes and HCC cannot be explained by
a greater frequency of HBV/HCV infections among diabetic
subjects. The increase of the RR is due to the fact that no
control with hepatitis reported a history of diabetes.Thus, the
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models including a term for hepatitis were largely unstable
and consequently were not considered in the main analyses.
Third, in our models, we were unable to allow for overweight
and obesity, which are strongly related to type 2 diabetes and
have been positively associated with the risk of liver cancer
[41, 42]. Such an association is partially or largely due to
hyperinsulinemia and diabetes in overweight subjects, and
may therefore represent an overadjustment. Further, history
of diabetes and use of antidiabetic drugs was self-reported,
and only a few subjects reported information on duration
of diabetes. Our findings, however, were in agreement with
those reported in other case-control and cohort studies.
Moreover, self-reported history of diabetes has been reported
to be satisfactorily reliable [43] and the overall prevalence
of diabetes among controls is consistent with estimates from
national population-based surveys [44]. Finally, concerns
have been recently raised about a possible link between
long-acting insulin analogue (glargine) and increased risk
of selected cancers [39]. Information on the type of insulin
was available for 41 out of 51 patients reporting insulin
use. Among them, 19 used rapid-acting (e.g., insulin aspart,
insulin lispro, and insulin glulisine) or regular/short-acting
insulin, 9 used intermediate-acting (e.g., NPH) or long-acting
insulin (e.g., insulin detemir, insulin glargine), and the
remaining 13 patients used different types of insulin simul-
taneously. In particular, only 7 patients used insulin glargine,
alone or in combination with other types of insulin. There-
fore, numbers were too limited to analyze the different insulin
types separately.
5. Conclusions
Our study confirms the over 2-fold excess risk of HCC in
diabetics and suggests that use of metformin may reduce
the risk of HCC, while insulin may increase the risk. The
diabetes-related excess risk is even greater in diabetic subjects
who are also tobacco smokers, the two factors combined
yielding an over 6-fold increased risk. The attributable risk
in this population is 17% for diabetes alone and 37% for
diabetes and tobacco combined. This is an additional reason
confirming the importance of stopping smoking in diabetics.
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